Patients TMS works. Why do fewer than 1% of eligible patients get it? A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.
Patients Why “rare disease” is a regulatory label, not a patient real... Regulators define a rare disease by how many people have it, and the answer depends on who is counting.
Patients From bedside to breakthroughs: Reimagining the human experie... Patients should be involved in the programme design process from the beginning, as co-creators with full influence over the outcome.
Patients Breaking Bipolar I disorder stigma in the Hispanic community For many Hispanic patients and families, that is where the gap between need and treatment can begin.
Patients Durability and earlier access could reshape diabetic retinop... This year’s World Sight Day turns global attention to the scale of preventable vision loss
Oncology On the benefits of earlier oncological intervention, with Jo... As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
